Diagens Tech chair Ning Song says medical AI future favors customized clinician copilots over single model

By Public Technologies
  • Diagens Tech management outlined its strategy for scaling medical imaging AI at the 2026 Festival of Medical AI on Sept. 25.
  • Chairman Ning Song backed a fragmented market, aiming to let individual radiologists train customized “AI Copilot” tools on iMedImage.
  • Song positioned iMedLoop as the company’s core asset, designed to industrialize continuous model creation via deployment feedback loops.
  • Kevin Kelly framed the shift as “AI does medicine, humans do doctoring,” with clinicians focusing on judgement, empathy, counselling.
  • Song argued the biggest payoff is broader access to scarce high-quality care, targeting population-wide efficiency gains over elite segments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Diagens Biotechnology Co. Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2405898_en) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.